Compare VS & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VS | BIVI |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 10.3M |
| IPO Year | N/A | 2013 |
| Metric | VS | BIVI |
|---|---|---|
| Price | $1.35 | $1.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 60.3K | ★ 212.1K |
| Earning Date | 04-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.75 | $1.06 |
| 52 Week High | $2.72 | $7.17 |
| Indicator | VS | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 40.46 |
| Support Level | $1.17 | $1.19 |
| Resistance Level | $1.78 | $1.40 |
| Average True Range (ATR) | 0.13 | 0.20 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 8.93 | 12.86 |
Versus Systems Inc operates within the technology sector, focusing on engagement-enhancing solutions through its proprietary prizing and promotions platform. This technology enables developers and content creators across streaming, live events, broadcast, gaming, and other media to integrate real-world prizes into their experiences, fostering greater consumer interaction and providing a compelling opportunity for brand partners and advertisers. The company operates in Canada and the USA.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.